Journal of Cellular and Molecular Medicine · 2020 · 60 citations · 39 references
MedicineOncologyPharmacologyCancer PharmacologyMolecular OncologyOncology PharmacotherapyGenitourinary Cancer PharmacotherapyHormonal Cancer TherapyOncogenic Signaling PathwaysProstate CancerTargeted Cancer TherapyTargeted TherapyAdvanced Prostate Cancer TherapyAndrogen Receptor TargetingHistone Deacetylase TargetsHistone DeacetylasesPhosphatidylinositol 3-Kinase-akt PathwayPi3k InhibitorsPi3k SignalingPi3k-akt Signaling Pathway
Targeting the androgen receptor (AR) signalling pathway remains the main therapeutic option for advanced prostate cancer. However, resistance to AR-targeting inhibitors represents a great challenge, highlighting the need for new therapies. Activation of the PI3K/AKT pathway and increased expression of histone deacetylases (HDACs) are common aberrations in prostate cancer, suggesting that inhibition of such targets may be a viable therapeutic strategy for this patient population. Previous reports demonstrated that combination of PI3K inhibitors (PI3KIs) with histone deacetylase inhibitors (HDACIs) resulted in synergistic antitumour activities against preclinical models of prostate cancer. In this study, we demonstrate that the novel dual PI3K and HDAC inhibitor CUDC-907 has promising antitumour activity against prostate cancer cell lines in vitro and castration-resistant LuCaP 35CR patient-derived xenograft (PDX) mouse model in vivo. CUDC-907-induced apoptosis was partially dependent on Mcl-1, Bcl-xL, Bim and c-Myc. Further, down-regulation of Wee1, CHK1, RRM1 and RRM2 contributed to CUDC-907-induced DNA damage and apoptosis. In the LuCaP 35CR PDX model, treatment with CUDC-907 resulted in significant inhibition of tumour growth. These findings support the clinical development of CUDC-907 for the treatment of prostate cancer.
39
Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2019 · 21K citations · Full text
Sulforhodamine B colorimetric assay for cytotoxicity screening
Vanicha Vichai, Kanyawim Kirtikara · Nature Protocols · 2006 · 3.7K citations
Integrative Clinical Genomics of Advanced Prostate Cancer
Dan R. Robinson, Eliezer M. Van Allen, Yi-Mi Wu et al. · Cell · 2015 · 3.6K citations · Full text
The Molecular Taxonomy of Primary Prostate Cancer
Adam Abeshouse, Jaeil Ahn, Rehan Akbani et al. · Cell · 2015 · 3.2K citations · Full text